Crossmark

Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Crossref DOI link: https://doi.org/10.1007/s11523-022-00881-2

Published Online: 2022-04-12

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shimizu, Toshio https://orcid.org/0000-0001-6632-0638
Kuboki, Yasutoshi https://orcid.org/0000-0003-3675-953X
Lin, Chia-Chi https://orcid.org/0000-0002-2573-5789
Yonemori, Kan https://orcid.org/0000-0002-7624-7611
Yanai, Tomoko https://orcid.org/0000-0002-2753-5078
Faller, Douglas V. https://orcid.org/0000-0002-2454-3478
Dobler, lwona https://orcid.org/0000-0001-5911-852X
Gupta, Neeraj https://orcid.org/0000-0002-5500-5218
Sedarati, Farhad

Kim, Kyu-pyo https://orcid.org/0000-0001-7848-5923
License Information

Text and Data Mining valid from 2022-04-12

Version of Record valid from 2022-04-12
More Information

Article History

First Online: 12 April 2022